• Kyodo

  • SHARE

A cross-border coalition of medicines regulators has begun exploring alternatives to large-scale clinical trials when it comes to evaluating the efficacy and safety of coronavirus vaccines, as it is becoming difficult for latecomers to secure enough study participants.

If the International Coalition of Medicines Regulatory Authorities finds other effective ways, drugmakers in Japan and other countries trailing the United States and European countries in COVID-19 vaccine development would be able to accelerate their development and production.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)